Not coincidentally, a recent study found that Gal-9 upregulation by anthracyclines is a novel mechanism mediating tumor immune escape, and Sun X et al. identified the combination of adriamycin and anti-Gal-9 therapies as a promising strategy for cancer treatment (Sun et al., 2023). This evidence concerns the gene LGALS9 and cancer.